---
title: "Evolus, Inc. 1Q 2026: Revenue $73.14M, EPS ($0.16) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285124185.md"
description: "Evolus, Inc. reported a 6.7% year-over-year revenue increase to $73.14M for Q1 2026, with a narrowed net loss of $10.67M and diluted EPS of ($0.16). The revenue growth was attributed to the Evolysse® launch and international expansion of Jeuveau®. The company is focusing on the cash-pay aesthetic channel and plans to launch the full Evolysse® line in Europe in Q2 2026. Additionally, a $30M revolving credit facility was opened in March 2026 to support operations."
datetime: "2026-05-04T21:11:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285124185.md)
  - [en](https://longbridge.com/en/news/285124185.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285124185.md)
---

# Evolus, Inc. 1Q 2026: Revenue $73.14M, EPS ($0.16) — 10-Q Summary

Evolus, Inc. reported first-quarter 2026 results with revenue up 6.7% year over year to $73.14M, narrowing its net loss to ($10.67M) and reducing diluted loss per share to ($0.16) versus ($0.3) in the year-ago quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$73.14M

$68.52M

6.7%

Net income²

($10.67M)

($18.89M)

43.5%

Diluted EPS³

($0.16)

($0.3)

46.7%

_¹ Reported as “Total net revenues”. ² Reported as “Net loss”. ³ Reported as “loss per share, basic and diluted”._

**Business Highlights**

-   Revenue growth was driven by the Evolysse® launch and international expansion of Jeuveau® across the U.S., Canada, select European markets and Australia.
-   Company shifted commercial focus to the cash-pay aesthetic channel with loyalty programs, co‑marketing, bundles and promotions to accelerate Evolysse® adoption.
-   Product rollout activity: U.S. launch of Evolysse® Form and Smooth (April 2025); full Evolysse® line planned for Europe in Q2 2026, with additional approvals expected in 2026–2027.
-   Operational developments included opening a $30M revolving credit facility in March 2026 and ongoing EU commercialization preparation for Evolysse®.

Original SEC Filing: Evolus, Inc. \[ EOLS \] - 10-Q - May. 04, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [EOLS.US](https://longbridge.com/en/quote/EOLS.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)